Ananda Pharma Plc — Regulatory Filings 2023

Nov 8, 2023

National Storage Mechanism | Additional information

RNS Number : 6882S

Ananda Developments PLC

08 November 2023

8 November 2023

ANANDA DEVELOPMENTS PLC

("Ananda" or the "Company")

THC Oil Patent Application Filed

Ananda Developments plc (AQSE: ANA), a company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of chronic, complex inflammatory pain conditions, is pleased to announce that its wholly owned subsidiary MRX Medical Limited (MRX) has filed a fifth patent application with the UK Government's Intellectual Property Office.

The application covers a new cannabinoid formulation known as MRX2T. This formulation is based on MRX's patent pending MRX2 cannabidiol formulation, with the addition of tetrahydrocannabinol (THC). This formulation has been developed for use in Randomised Controlled Trials (RCTs)  and the Company looks forward to updating shareholders in due course.

This application is in addition to four previous applications which cover the proprietary formulation methodology and three different cannabinoid formulations known as MRX1, MRX2 and MRX3. MRX1 will be used as the investigational medicinal product (IMP) in two Phase II RCTs being conducted by the University of Edinburgh. One trial is investigating the effect of CBD on pain associated with chemotherapy induced peripheral neuropathy (CIPN) and the other is investigating the effect of cannabidiol on pain associated with endometriosis.

Ananda's CEO, Melissa Sturgess, commented: "We are building Ananda's intellectual property with the application for a fifth patent covering an oil formulation containing THC as well as CBD.  We are hopeful this oil will be used in randomised controlled trials and look forward to bringing shareholders an update on this as soon as possible."

To stay abreast of the latest developments at Ananda, we encourage you to follow our social media channels which are:   

·    Instagram: https://instagram.com/anandadevelopments?igshid=YmMyMTA2M2Y=   

·    LinkedIn: https://www.linkedin.com/company/anadevelopments/

·    Twitter: https://twitter.com/anandaplc?s=21&t=9yeIC_xYCfzgDn7j26sfuA   

-Ends-

The Directors of the Company accept responsibility for the contents of this announcement.

ANANDA DEVELOPMENTS PLC	+44 (0)7463 686 497
	[email protected]
Chief Executive Officer
Melissa Sturgess
Executive Director
Jeremy Sturgess-Smith
SP ANGEL CORPORATE FINANCE LLP	+44 (0)20 3470 0470
Corporate Finance
Richard Morrison
Harry Davies-Ball
Corporate Broking
Abigail Wayne
Rob Rees

About Ananda Developments

Ananda is an AQSE-listed company whose ambition is to be a leading provider of cannabinoid-based medicines for the treatment of complex, chronic inflammatory pain conditions.

For more information, please visit: https://anandadevelopments.com/

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXUBUNROAUARAA